{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:51:12Z","timestamp":1791168672000,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Natural Science Foundation of Shandong Province","award":["ZR2025MS1335"],"award-info":[{"award-number":["ZR2025MS1335"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073729, 82273819"],"award-info":[{"award-number":["82073729, 82273819"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11607-1","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:51:38Z","timestamp":1780051898000},"page":"7441-7457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Naphthalene-based hydroxamate HDAC inhibitors with anti-breast tumor activity"],"prefix":"10.1007","volume":"30","author":[{"given":"Hui","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-Hao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"1","key":"11607_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"11607_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S1470-2045(25)00730-2","volume":"27","author":"regional Global","year":"2026","unstructured":"Global regional, national burden of breast cancer among females (2026) 1990\u20132023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023. Lancet Oncol 27(3):302\u2013326","journal-title":"Lancet Oncol"},{"issue":"11","key":"11607_CR3","doi-asserted-by":"publisher","first-page":"e2443198","DOI":"10.1001\/jamanetworkopen.2024.43198","volume":"7","author":"HM Bizuayehu","year":"2024","unstructured":"Bizuayehu HM, Ahmed KY, Kibret GD, Dadi AF, Belachew SA, Bagade T, Tegegne TK, Venchiarutti RL, Kibret KT, Hailegebireal AH, Assefa Y, Khan MN, Abajobir A, Alene KA, Mengesha Z, Erku D, Enquobahrie DA, Minas TZ, Misgan E, Ross AG (2024) Global Disparities of cancer and its projected burden in 2050. JAMA Netw Open 7(11):e2443198","journal-title":"JAMA Netw Open"},{"key":"11607_CR4","doi-asserted-by":"publisher","first-page":"217883","DOI":"10.1016\/j.canlet.2025.217883","volume":"629","author":"J Liang","year":"2025","unstructured":"Liang J, Lin Y, Wang W, Ni J, Lin H, Huang Z, Qi J, Tan Z, Liang H, He J (2025) Global cancer burden forecast for 204 countries and territories, 2022\u20132050: a predictive analysis from the global burden of disease study 2021. Cancer Lett 629:217883","journal-title":"Cancer Lett"},{"issue":"9","key":"11607_CR5","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1016\/j.bmc.2016.12.001","volume":"25","author":"J Zang","year":"2017","unstructured":"Zang J, Shi B, Liang X, Gao Q, Xu W, Zhang Y (2017) Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity. Bioorg Med Chem 25(9):2666\u20132675","journal-title":"Bioorg Med Chem"},{"issue":"10","key":"11607_CR6","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.bbapap.2016.06.007","volume":"1864","author":"A Drazic","year":"2016","unstructured":"Drazic A, Myklebust LM, Ree R, Arnesen T (2016) The world of protein acetylation. Biochim Biophys Acta 1864(10):1372\u20131401","journal-title":"Biochim Biophys Acta"},{"key":"11607_CR7","doi-asserted-by":"publisher","first-page":"865975","DOI":"10.3389\/fimmu.2022.865975","volume":"13","author":"P Ding","year":"2022","unstructured":"Ding P, Ma Z, Liu D, Pan M, Li H, Feng Y, Zhang Y, Shao C, Jiang M, Lu D, Han J, Wang J, Yan X (2022) Lysine acetylation\/deacetylation modification of immune-related molecules in cancer immunotherapy. Front Immunol 13:865975","journal-title":"Front Immunol"},{"key":"11607_CR8","doi-asserted-by":"publisher","first-page":"116129","DOI":"10.1016\/j.ejmech.2024.116129","volume":"265","author":"B Cheng","year":"2024","unstructured":"Cheng B, Pan W, Xiao Y, Ding Z, Zhou Y, Fei X, Liu J, Su Z, Peng X, Chen J (2024) HDAC-targeting epigenetic modulators for cancer immunotherapy. Eur J Med Chem 265:116129","journal-title":"Eur J Med Chem"},{"issue":"7","key":"11607_CR9","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18(7):1414","journal-title":"Int J Mol Sci"},{"key":"11607_CR10","doi-asserted-by":"publisher","first-page":"105695","DOI":"10.1016\/j.phrs.2021.105695","volume":"170","author":"MG Shetty","year":"2021","unstructured":"Shetty MG, Pai P, Deaver RE, Satyamoorthy K, Babitha KS (2021) Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy. Pharmacol Res 170:105695","journal-title":"Pharmacol Res"},{"issue":"51","key":"11607_CR11","doi-asserted-by":"publisher","first-page":"42428","DOI":"10.1074\/jbc.R112.372300","volume":"287","author":"H Yuan","year":"2012","unstructured":"Yuan H, Marmorstein R (2012) Structural basis for sirtuin activity and inhibition. J Biol Chem 287(51):42428\u201342435","journal-title":"J Biol Chem"},{"issue":"7384","key":"11607_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature10804","volume":"482","author":"YY Lin","year":"2012","unstructured":"Lin YY, Kiihl S, Suhail Y, Liu SY, Chou YH, Kuang Z, Lu JY, Khor CN, Lin CL, Bader JS, Irizarry R, Boeke JD (2012) Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK. Nature 482(7384):251\u2013255","journal-title":"Nature"},{"issue":"6810","key":"11607_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/35042612","volume":"408","author":"J Luo","year":"2000","unstructured":"Luo J, Su F, Chen D, Shiloh A, Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408(6810):377\u2013381","journal-title":"Nature"},{"issue":"6887","key":"11607_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/417455a","volume":"417","author":"C Hubbert","year":"2002","unstructured":"Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417(6887):455\u2013458","journal-title":"Nature"},{"issue":"1","key":"11607_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nbt1272","volume":"25","author":"PA Marks","year":"2007","unstructured":"Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25(1):84\u201390","journal-title":"Nat Biotechnol"},{"issue":"4","key":"11607_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/2040620715592567","volume":"6","author":"A Sawas","year":"2015","unstructured":"Sawas A, Radeski D, O\u2019Connor OA (2015) Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol 6(4):202\u2013208","journal-title":"Ther Adv Hematol"},{"key":"11607_CR17","first-page":"269","volume":"6","author":"H Bailey","year":"2015","unstructured":"Bailey H, Stenehjem DD, Sharma S (2015) Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med 6:269\u2013276","journal-title":"J Blood Med"},{"key":"11607_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.critrevonc.2016.07.001","volume":"106","author":"SA Reddy","year":"2016","unstructured":"Reddy SA (2016) Romidepsin for the treatment of relapsed\/refractory cutaneous T-cell lymphoma (mycosis fungoides\/Sezary syndrome): use in a community setting. Crit Rev Oncol Hematol 106:99\u2013107","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"11607_CR19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"ZQ Ning","year":"2012","unstructured":"Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP (2012) Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 69(4):901\u2013909","journal-title":"Cancer Chemother Pharmacol"},{"key":"11607_CR20","doi-asserted-by":"crossref","unstructured":"Lamb YN (2024) Givinostat: first approval drugs 84(7):849\u2013856","DOI":"10.1007\/s40265-024-02052-1"},{"issue":"1","key":"11607_CR21","doi-asserted-by":"publisher","first-page":"e14366","DOI":"10.1111\/cbdd.14366","volume":"103","author":"H Han","year":"2024","unstructured":"Han H, Feng X, He T, Wu Y, He T, Yue Z, Zhou W (2024) Discussion on structure classification and regulation function of histone deacetylase and their inhibitor. Chem Biol Drug Des 103(1):e14366","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"11607_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1021\/acsmedchemlett.7b00414","volume":"9","author":"W Chen","year":"2018","unstructured":"Chen W, Dong G, Wu Y, Zhang W, Miao C, Sheng C (2018) Dual NAMPT\/HDAC inhibitors as a new strategy for multitargeting antitumor drug discovery. ACS Med Chem Lett 9(1):34\u201338","journal-title":"ACS Med Chem Lett"},{"key":"11607_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jmgm.2016.10.007","volume":"70","author":"M Hassanzadeh","year":"2016","unstructured":"Hassanzadeh M, Bagherzadeh K, Amanlou M (2016) A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors. J Mol Graph Model 70:170\u2013180","journal-title":"J Mol Graph Model"},{"issue":"1","key":"11607_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s43094-022-00400-0","volume":"8","author":"ZM Mazayen","year":"2022","unstructured":"Mazayen ZM, Ghoneim AM, Elbatanony RS, Basalious EB, Bendas ER (2022) Pharmaceutical nanotechnology: from the bench to the market. Futur J Pharm Sci 8(1):12","journal-title":"Futur J Pharm Sci"},{"issue":"6","key":"11607_CR25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199733060-00001","volume":"33","author":"NM Davies","year":"1997","unstructured":"Davies NM (1997) Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet 33(6):404\u2013416","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"11607_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bmcl.2006.09.085","volume":"17","author":"CM Marson","year":"2007","unstructured":"Marson CM, Mahadevan T, Dines J, Sengmany S, Morrell JM, Alao JP, Joel SP, Vigushin DM, Coombes RC (2007) Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase, Bioorg. Med Chem Lett 17(1):136\u2013141","journal-title":"Med Chem Lett"},{"issue":"5","key":"11607_CR27","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1021\/acs.jmedchem.4c03084","volume":"68","author":"H Tian","year":"2025","unstructured":"Tian H, Liu Y, Lin S, Deng J, Zhang Q, Hao F, Tang Y, Xiong T, Zhang K, Shi G, Luo L, Peng S, Sheng L, Ji M, Xu H (2025) Design, synthesis, and biological evaluation of novel Fms-like tyrosine kinase 3\/VEGFR2\/histone deacetylase inhibitors for the treatment of acute myeloid Leukemia. J Med Chem 68(5):5736\u20135759","journal-title":"J Med Chem"},{"issue":"1","key":"11607_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41420-025-02679-3","volume":"11","author":"P Shan","year":"2025","unstructured":"Shan P, Liu KL, Jiang X, Zhou G, Zhu K, Zhang H (2025) Discovery of a novel potent tubulin inhibitor through virtual screening and target validation for cancer chemotherapy. Cell Death Discov 11(1):392","journal-title":"Cell Death Discov"},{"issue":"5","key":"11607_CR29","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.apsb.2024.02.012","volume":"14","author":"P Shan","year":"2024","unstructured":"Shan P, Ye T, Tang YD, Song H, Wang C, Zhu K, Yang F, Zhang SL, Su PW, Gao S, Zhang H (2024) First total synthesis, antitumor evaluation and target identification of mornaphthoate E: a new tubulin inhibitor template acting on PI3K\/Akt signaling pathway. Acta Pharm Sin B 14(5):2177\u20132193","journal-title":"Acta Pharm Sin B"},{"key":"11607_CR30","doi-asserted-by":"publisher","first-page":"116220","DOI":"10.1016\/j.ejmech.2024.116220","volume":"268","author":"YP Li","year":"2024","unstructured":"Li YP, Liu H, Zhao XC, Tang XL, Shan P, Zhang H (2024) Rare flavanone-diarylheptanoid hybrids from Typha angustifolia shows anti breast cancer activity via activating TGF-beta1\/Smad signaling pathway. Eur J Med Chem 268:116220","journal-title":"Eur J Med Chem"},{"key":"11607_CR31","doi-asserted-by":"publisher","first-page":"106741","DOI":"10.1016\/j.bioorg.2023.106741","volume":"139","author":"P Shan","year":"2023","unstructured":"Shan P, Wang C, Chen H, Yu J, Zhang H (2023) Inonotsutriol E from Inonotus obliquus exhibits promising anti breast cancer activity via regulating the JAK2\/STAT3 signaling pathway. Bioorg Chem 139:106741","journal-title":"Bioorg Chem"},{"key":"11607_CR32","doi-asserted-by":"publisher","first-page":"106803","DOI":"10.1016\/j.bioorg.2023.106803","volume":"140","author":"RF Ma","year":"2023","unstructured":"Ma RF, Liu H, Zhao XC, Shan P, Sun P, Xue JJ, Wei G, Zhang H (2023) Meroterpenoids from Daphne genkwa shows promising in vitro antitumor activity via inhibiting PI3K\/Akt\/mTOR signaling pathway in A549 cells. Bioorg Chem 140:106803","journal-title":"Bioorg Chem"},{"issue":"7","key":"11607_CR33","doi-asserted-by":"publisher","first-page":"e202400792","DOI":"10.1002\/cbdv.202400792","volume":"21","author":"XC Zhao","year":"2024","unstructured":"Zhao XC, Ma RF, Liu H, Shan P, Bao J, Zhang H (2024) Grifolin induces cell death of human lung cancer A549 cell line via inhibiting KRAS-mediated multiple signaling pathways. Chem Biodivers 21(7):e202400792","journal-title":"Chem Biodivers"},{"key":"11607_CR34","doi-asserted-by":"crossref","unstructured":"Smith JR, Toro A, Sabater A, Kovacic S, Ban F, Arevalo AP, Crispo M, Gueron G, Young RN, Cherkasov A (2026) Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection. 16:6905","DOI":"10.1038\/s41598-026-36842-2"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11607-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11607-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11607-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:02:44Z","timestamp":1791165764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11607-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11607"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11607-1","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}